Literature DB >> 17391446

A clinical study of 77 patients with mucopolysaccharidosis type II.

Ida V D Schwartz1, Márcia G Ribeiro, João G Mota, Maria Betânia P Toralles, Patrícia Correia, Dafne Horovitz, Emerson S Santos, Isabella L Monlleo, Agnes C Fett-Conte, Ruy P Oliveira Sobrinho, Denise Y J Norato, Anna Carolina Paula, Chong A Kim, Andréa R Duarte, Raquel Boy, Eugênia Valadares, Maria De Michelena, Paulina Mabe, Cyro D Martinhago, João M Pina-Neto, Fernando Kok, Sandra Leistner-Segal, Maira G Burin, Roberto Giugliani.   

Abstract

AIM: This study aims to assess the clinical features of 77 South American patients (73 Brazilian) with mucopolysaccharidosis type II (MPS II).
METHODS: Details of the patients and their disease manifestations were obtained from a review of medical records, interviews with the patients and/or their families, and physical examination of the patients.
RESULTS: Mean birth weight was 3360 g, median age at onset of symptoms was 18 months and median age at diagnosis was 6 years. For the whole sample (median age, 8.2 years; range, 2.8-53.0 years), neurological degeneration, typical pebbly skin lesions, seizures and extensive dermal melanocytosis were found in 23.3, 13.0, 13.0 and 1.3% of the cases, respectively. The most frequently reported echocardiogram abnormality was mitral valve regurgitation. Refraction errors were the most common ophthalmological manifestation. The following characteristics were found to be associated with the severe form of MPS II: earlier age at biochemical diagnosis, higher levels of urinary glycosaminoglycans, language development delay, behavioural disturbances, poor school performance and mental retardation.
CONCLUSION: Our results suggest that there is a considerable delay between the onset of signs and symptoms and the diagnosis of MPS II in Brazil (and probably in South America as well), and that many complications of this disease are underdiagnosed and undertreated. Therefore, the implementation of programmes aiming to increase the awareness of the disease, the availability of biochemical diagnostic tests and the provision of better support to affected patients is urgently needed.

Entities:  

Mesh:

Year:  2007        PMID: 17391446     DOI: 10.1111/j.1651-2227.2007.00212.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  51 in total

1.  Health-Related Quality of Life in Patients with MPS II.

Authors:  Mary Needham; Wendy Packman; Natasha Quinn; Maxwell Rappoport; Christa Aoki; Alan Bostrom; Matthew Cordova; Sandra Macias; Cynthia Morgan; Seymour Packman
Journal:  J Genet Couns       Date:  2014-11-14       Impact factor: 2.537

2.  Detection by Urinary GAG Testing of Mucopolysaccharidosis Type II in an At-Risk Spanish Population.

Authors:  Laura López-Marín; Luis G Gutiérrez-Solana; Luis Aldamiz-Echevarria Azuara; Rogelio Simón de Las Heras; Anna Duat Rodríguez; Verónica Cantarín Extremera
Journal:  JIMD Rep       Date:  2013-02-02

3.  Mucopolysaccharidosis Type II and the G374sp Mutation.

Authors:  E Martínez-Quintana; F Rodríguez-González
Journal:  Mol Syndromol       Date:  2013-02-13

4.  Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy.

Authors:  Osvaldo Artigalás; Valeska Lizzi Lagranha; Maria Luiza Saraiva-Pereira; Maira Graeff Burin; Charles Marques Lourenço; Hélio van der Linden; Mara Lúcia Ferreira Santos; Sergio Rosemberg; Carlos Eduardo Steiner; Fernando Kok; Carolina F Moura de Souza; Laura B Jardim; Roberto Giugliani; Ida Vanessa Schwartz
Journal:  J Inherit Metab Dis       Date:  2010-07-02       Impact factor: 4.982

Review 5.  Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.

Authors:  E M Cross; D J Hare
Journal:  J Inherit Metab Dis       Date:  2013-02-06       Impact factor: 4.982

6.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

7.  Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sung Yoon Cho; Rimm Huh; Mi Sun Chang; Jieun Lee; Younghee Kwun; Se Hyun Maeng; Su Jin Kim; Young Bae Sohn; Sung Won Park; Eun-Kyung Kwon; Sun Ju Han; Jooyoun Jung; Dong-Kyu Jin
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

8.  Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution.

Authors:  Renzo Manara; Angelica Rampazzo; Mara Cananzi; Leonardo Salviati; Rodica Mardari; Paola Drigo; Rosella Tomanin; Nicoletta Gasparotto; Elena Priante; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-01-06       Impact factor: 4.982

9.  MPS II: adaptive behavior of patients and impact on the family system.

Authors:  Mary Needham; Wendy Packman; Maxwell Rappoport; Natasha Quinn; Matthew Cordova; Sandra Macias; Cynthia Morgan; Seymour Packman
Journal:  J Genet Couns       Date:  2013-11-06       Impact factor: 2.537

10.  Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.

Authors:  T Andrew Burrow; Nancy D Leslie
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.